Phenotypes and Clinical Outcome of Heart Failure With Preserved Ejection Fraction Patients in China: Findings From the Chinese Cardiovascular Association Database-Heart Failure Center Registry

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous syndrome that poses challenges for therapeutic development and contributes to suboptimal patient outcomes. The phenotypic classification of patients with HFpEF to guide etiology-specific therapeutic strategies represents a rational approach to address the current dilemma. However, the clinical outcomes of HFpEF under different etiological classifications remain poorly understood. Here, we assessed the clinical outcomes of HFpEF patients across different etiological phenotypes, based on a novel classification system comprising five categories: vascular-related, cardiomyopathy-related, right heart/pulmonary-related, valvular/rhythm-related, and extracardiac disease-related HFpEF. Data from the Chinese Cardiovascular Association Database-Heart Failure Center Registry (2017–2021) were analyzed, including 51,466 hospitalized HFpEF patients with 1-year follow-up. Significant differences in baseline characteristics and clinical outcomes were observed among phenotypes. Patients with right heart/pulmonary-related, valvular/rhythm-related, and extracardiac disease-related HFpEF showed a higher incidence of adverse outcomes. Specifically, the right heart/pulmonary-related and valvular/rhythm-related phenotypes were associated with increased heart failure rehospitalization, while extracardiac disease-related HFpEF was linked to higher cardiovascular mortality. Prognostic risk factors also varied across phenotypes. In conclusion, 1-year outcomes exhibit significant variations across HFpEF phenotypic subgroups. Future studies should explore whether phenotype-specific personalized treatment strategies can improve clinical outcomes, especially in high-risk phenotypes.

Keywords

clinical outcomes / etiological phenotypes / heart failure with preserved ejection fraction / risk factors / treatment strategies

References

[1] Z. Long, Y. Xu, W. Liu, et al., “Mortality Trend of Heart Diseases in China, 2013–2020,” Cardiology Plus 7, no. 3 (2022): 111–117.

[2] M. Fu and K. Swedberg, “Enhancing Implementation of Evidence-Based Heart Failure Therapies in Clinical Practice: Vital to Modern Medicine,” Cardiology Plus 9, no. 1 (2024): 6–8.

[3] GBD 2019 Diseases and Injuries Collaborators, “Global Burden of 369 Diseases and Injuries in 204 Countries and territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019,” Lancet 396, no. 10258 (2020): 1204–1222.

[4] S. S. Martin, A. W. Aday, Z. I. Almarzooq, et al., “2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association,” Circulation 149, no. 8 (2024): e347–e913.

[5] H. Wang, K. Chai, M. Du, et al., “Prevalence and Incidence of Heart Failure among Urban Patients in China: A National Population-Based Analysis,” Circulation: Heart Failure 14, no. 10 (2021): e008406.

[6] T. A. McDonagh, M. Metra, M. Adamo, et al., “2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure,” European Heart Journal 44, no. 37 (2023): 3627–3639.

[7] P. A. Heidenreich, B. Bozkurt, D. Aguilar, et al., “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation 145, no. 18 (2022): e895–e1032.

[8] M. Vaduganathan, R. J. Mentz, B. L. Claggett, et al., “Sacubitril/Valsartan in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Pre-specified Participant-Level Pooled Analysis of PARAGLIDE-HF and PARAGON-HF,” European Heart Journal 44, no. 31 (2023): 2982–2993.

[9] S. D. Solomon, J. J. V. McMurray, I. S. Anand, et al., “Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction,” New England Journal of Medicine 381, no. 17 (2019): 1609–1620.

[10] S. D. Anker, J. Butler, G. Filippatos, et al., “Empagliflozin in Heart Failure With a Preserved Ejection Fraction,” New England Journal of Medicine 385, no. 16 (2021): 1451–1461.

[11] M. M. Redfield and B. A. Borlaug, “Heart Failure with Preserved Ejection Fraction: A Review,” JAMA 329, no. 10 (2023): 827–838.

[12] S. D. Solomon, M. Vaduganathan, B. L. Claggett, et al., “Baseline Characteristics of Patients with HF with Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial,” JACC: Heart Failure 10, no. 3 (2022): 184–197.

[13] S. D. Solomon, M. Vaduganathan, B. LC, et al., “Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure,” Circulation 141, no. 5 (2020): 352–361.

[14] S. D. Solomon, B. Claggett, E. F. Lewis, et al., “Influence of Ejection Fraction on Outcomes and Efficacy of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction,” European Heart Journal 37, no. 5 (2016): 455–462.

[15] J. B. Cohen, S. J. Schrauben, L. Zhao, et al., “Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone,” JACC: Heart Failure 8, no. 3 (2020): 172–184.

[16] S. J. Shah, D. H. Katz, S. Selvaraj, et al., “Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction,” Circulation 131, no. 3 (2015): 269–279.

[17] D. P. Kao, J. D. Lewsey, I. S. Anand, et al., “Characterization of Subgroups of Heart Failure Patients With Preserved Ejection Fraction With Possible Implications for Prognosis and Treatment Response,” European Journal of Heart Failure 17, no. 9 (2015): 925–935.

[18] J. Ge, “Coding Proposal on Phenotyping Heart Failure With Preserved Ejection Fraction: A Practical Tool for Facilitating Etiology-oriented Therapy,” Cardiology Journal 27, no. 1 (2020): 97–98.

[19] H. Wang, Y. Y. Li, K. Chai, et al., “Contemporary Epidemiology and Treatment of Hospitalized Heart Failure Patients in Real Clinical Practice in China,” Zhonghua Xin Xue Guan Bing Za Zhi [Chinese Journal of Cardiovascular Diseases] 47, no. 11 (2019): 865–874.

[20] M. N. Kosiborod, J. Deanfield, R. Pratley, et al., “Semaglutide Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trials,” Lancet 404, no. 10456 (2024): 949–961.

[21] J. Tromp, T. H. Teng, W. T. Tay, et al., “Heart Failure With Preserved Ejection Fraction in Asia,” European Journal of Heart Failure 21, no. 1 (2019): 23–36.

[22] O. Chioncel, M. Lainscak, P. M. Seferovic, et al., “Epidemiology and One-Year Outcomes in Patients With Chronic Heart Failure and Preserved, Mid-Range and Reduced Ejection Fraction: An Analysis of the ESC Heart Failure Long-Term Registry,” European Journal of Heart Failure 19, no. 12 (2017): 1574–1585.

[23] A. Cai, W. Qiu, Y. Zhou, et al., “Clinical Characteristics and 1-Year Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction: Results From the China Cardiovascular Association Database-Heart Failure Center Registry,” European Journal of Heart Failure 24, no. 11 (2022): 2048–2062.

[24] M. A. Pfeffer, A. M. Shah, and B. A. Borlaug, “Heart Failure with Preserved Ejection Fraction in Perspective,” Circulation Research 124, no. 11 (2019): 1598–1617.

[25] C. J. Rush, C. Berry, K. G. Oldroyd, et al., “Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction,” JAMA Cardiology 6, no. 10 (2021): 1130–1143.

[26] P. G. Camici, C. Tschöpe, M. F. Di Carli, O. Rimoldi, and S. Van Linthout, “Coronary Microvascular Dysfunction in Hypertrophy and Heart Failure,” Cardiovascular Research 116, no. 4 (2020): 806–816.

[27] S. J. Pocock, J. P. Ferreira, M. Packer, et al., “Biomarker-driven Prognostic Models in Chronic Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial,” European Journal of Heart Failure 24, no. 10 (2022): 1869–1878.

[28] C. Gulea, R. Zakeri, and J. K. Quint, “Differences in Outcomes Between Heart Failure Phenotypes in Patients With Coexistent Chronic Obstructive Pulmonary Disease: A Cohort Study,” Annals of the American Thoracic Society 19, no. 6 (2022): 971–980.

[29] Y. R. Patel, K. E. Kurgansky, T. F. Imran, et al., “Prognostic Significance of Baseline Serum Sodium in Heart Failure with Preserved Ejection Fraction,” Journal of the American Heart Association 7, no. 12 (2018): e007529.

[30] Y. Sato, A. Yoshihisa, M. Oikawa, et al., “Hyponatremia at Discharge Is Associated With Adverse Prognosis in Acute Heart Failure Syndromes With Preserved Ejection Fraction: A Report From the JASPER Registry,” European Heart Journal Acute Cardiovascular Care 8, no. 7 (2019): 623–633.

[31] S. Selvaraj, B. L. Claggett, M. Böhm, et al., “Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated with Sacubitril/Valsartan,” Journal of the American College of Cardiology 75, no. 14 (2020): 1644–1656.

[32] P. M. Seferović, M. Polovina, J. Bauersachs, et al., “Heart Failure in Cardiomyopathies: A Position Paper From the Heart Failure Association of the European Society of Cardiology,” European Journal of Heart Failure 21, no. 5 (2019): 553–576.

[33] P. Melacini, C. Basso, A. Angelini, et al., “Clinicopathological Profiles of Progressive Heart Failure in Hypertrophic Cardiomyopathy,” European Heart Journal 31, no. 17 (2010): 2111–2123.

[34] I. Olivotto, F. Cecchi, C. Poggesi, and M. H. Yacoub, “Patterns of Disease Progression in Hypertrophic Cardiomyopathy: An Individualized Approach to Clinical Staging,” Circulation: Heart Failure 5, no. 4 (2012): 535–546.

[35] M. S. Maurer, P. Elliott, R. Comenzo, M. Semigran, and C. Rapezzi, “Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis,” Circulation 135, no. 14 (2017): 1357–1377.

[36] T. M. Gorter, E. S. Hoendermis, D. J. van Veldhuisen, et al., “Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-analysis,” European Journal of Heart Failure 18, no. 12 (2016): 1472–1487.

[37] S. F. Mohammed, I. Hussain, O. F. AbouEzzeddine, et al., “Right Ventricular Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study,” Circulation 130, no. 25 (2014): 2310–2320.

[38] T. M. Gorter, K. W. Streng, J. P. van Melle, et al., “Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction,” American Journal of Cardiology 121, no. 5 (2018): 621–627.

[39] S. Puwanant, T. C. Priester, F. Mookadam, C. J. Bruce, M. M. Redfield, and K. Chandrasekaran, “Right Ventricular Function in Patients With Preserved and Reduced Ejection Fraction Heart Failure,” European Journal of Echocardiography 10, no. 6 (2009): 733–737.

[40] T. M. Gorter, D. J. van Veldhuisen, J. Bauersachs, et al., “Right Heart Dysfunction and Failure in Heart Failure With Preserved Ejection Fraction: Mechanisms and Management. Position Statement on Behalf of the Heart Failure Association of the European Society of Cardiology,” European Journal of Heart Failure 20, no. 1 (2018): 16–37.

[41] D. L. Packer, J. P. Piccini, K. H. Monahan, et al., “Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial,” Circulation 143, no. 14 (2021): 1377–1390.

[42] P. Kirchhof, A. J. Camm, A. Goette, et al., “Early Rhythm-Control Therapy in Patients With Atrial Fibrillation,” New England Journal of Medicine 383, no. 14 (2020): 1305–1316.

[43] R. Itier, M. Guillaume, J. E. Ricci, et al., “Non-alcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction: From Pathophysiology to Practical Issues,” ESC Heart Failure 8, no. 2 (2021): 789–798.

[44] J. A. Naser, S. Pislaru, M. N. Stan, and G. Lin, “Incidence, Risk Factors, Natural History and Outcomes of Heart Failure in Patients With Graves' disease,” Heart 108, no. 11 (2022): 868–874.

[45] K. Komuro, J. Komuro, K. Ueno, H. Kaneko, and I. Komuro, “Physical Activity and Cardiac Rehabilitation for the Primary and Secondary Prevention of Heart Failure,” Cardiology Plus 9, no. 2 (2024): 103–110.

[46] “[Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2014],” Zhonghua Xin Xue Guan Bing Za Zhi [Chinese Journal of Cardiovascular Diseases] 42, no. 2 (2014): 98–122.

[47] B. F. Zhou, “Predictive Values of Body Mass Index and Waist Circumference for Risk Factors of Certain Related Diseases in Chinese Adults—Study on Optimal Cut-Off Points of Body Mass Index and Waist Circumference in Chinese Adults,” Biomedical and Environmental Sciences 15, no. 1 (2002): 83–96.

[48] A. S. Levey, J. Coresh, T. Greene, et al., “Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate,” Annals of Internal Medicine 145, no. 4 (2006): 247–254.

[49] X. Wang, Z. Wu, Y. Chen, et al., “Increased Prevalence and Incidence of Anemia Among Adults in Transforming Rural China: Two Cross-sectional Surveys,” BMC Public Health 15 (2015): 1302.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.